Welcome to our dedicated page for Inovio Pharmaceu news (Ticker: INO), a resource for investors and traders seeking the latest updates and insights on Inovio Pharmaceu stock.
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) is a biotechnology company developing DNA medicines for HPV-related diseases, cancer, and infectious diseases. The INO news feed on Stock Titan aggregates company-issued press releases, regulatory updates, and other market-moving disclosures so readers can follow how INOVIO’s DNA medicine programs progress over time.
A major focus of recent INOVIO news is INO-3107, an investigational DNA medicine for adults with recurrent respiratory papillomatosis (RRP), a rare HPV-related disease of the respiratory tract. Updates include completion of a rolling Biologics License Application (BLA), FDA acceptance of the BLA for review under a Standard classification, and discussion of the accelerated approval pathway. News items also highlight clinical data showing reductions in the number of surgeries required by trial participants and long-term durability results from retrospective analyses.
Investors can also find announcements on capital-raising transactions, such as underwritten public offerings of common stock and warrants disclosed in Form 8-K filings and related press releases. INOVIO frequently reports on financial results, including quarterly earnings releases, as well as corporate governance and compensation matters like inducement stock option grants under its Inducement Plan.
Additional coverage includes scientific and clinical milestones, such as publication of Phase 1 proof-of-concept data for DNA-Encoded Monoclonal Antibody (DMAb) technology in Nature Medicine and preclinical progress in DNA-encoded protein (DPROT) programs. Conference participation and investor events are also regular topics. For followers of INO stock, this news page offers a centralized view of the company’s clinical, regulatory, financial, and strategic communications.
INOVIO (NASDAQ: INO) reported Q4 and full-year 2025 results and business updates, including a BLA acceptance for INO-3107 with a PDUFA target date of October 30, 2026. The FDA noted a potential issue on accelerated approval eligibility and agreed to meet. The company reported $58.5M cash and a projected runway into Q4 2026.
2025 financials: R&D $54.2M, G&A $32.7M, total operating expenses $86.9M, and a full-year net loss of $84.9M. INOVIO highlighted published clinical data and collaborations advancing its DNA medicine pipeline.
INOVIO (NASDAQ:INO) will present at two scientific conferences in March 2026. Eurogin HPV Conference (Vienna) on March 19 at 8:00 AM CET: presentation on DNA immunotherapy INO-3107 and long-term surgical intervention reduction in HPV-6 and HPV-11 RRP. World Vaccine Congress DC (Washington, DC) on March 30 at 11:50 AM ET: presentation on DNA-encoded monoclonal antibody technology for durable, tolerable in vivo mAb expression targeting COVID. Available abstracts will be posted on INOVIO's website after presentations.
INOVIO (NASDAQ:INO) will release fourth quarter and full year 2025 financial results after market close on March 12, 2026.
Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss results and provide a general business update; the webcast will be archived for 90 days.
INOVIO (NASDAQ: INO) and Akeso announced a clinical collaboration to evaluate INO-5412 plus Akeso's cadonilimab in glioblastoma as part of the Phase 2 INSIGhT adaptive platform trial.
Dosing is expected to begin in H2 2026. The program builds on prior positive Phase 2 immune responses with INO-5401 and leverages cadonilimab's China approvals and ongoing Phase 3/registration studies.
INOVIO (NASDAQ:INO) announced participation in multiple scientific and investor conferences between Feb 18 and Mar 10, 2026. Management will present posters and talks on INO-3107, SARS-CoV-2 DMAbs phase 1 data, and hold investor fireside chats and one-on-one meetings.
Webcasts and replay links are provided for investor events; abstracts will be posted on the company website after each presentation.
INOVIO (NASDAQ: INO) announced the U.S. FDA accepted its Biologics License Application (BLA) for INO-3107 to treat adults with recurrent respiratory papillomatosis (RRP).
FDA assigned a PDUFA goal date of October 30, 2026 and classified the review as Standard. The FDA indicated it is not currently planning an advisory committee meeting.
The BLA was filed under the accelerated approval pathway; FDA flagged a potential review issue, preliminarily finding inadequate information to justify accelerated approval. INOVIO plans to request a meeting with FDA and continues to believe INO-3107 meets accelerated approval criteria. The BLA includes Phase 1/2 data and long-term durability results published in Nature Communications and The Laryngoscope.
INOVIO (NASDAQ: INO) announced an equity inducement grant under its 2022 Inducement Plan for a newly hired employee. The Compensation Committee approved an option to purchase 24,000 shares with a Grant Date of November 28, 2025.
The option has an exercise price of $2.06 (INOVIO closing price on the Grant Date) and vests over three years with one-third vesting on each of the first, second and third anniversaries of the Grant Date, subject to continued employment and the terms of the stock option agreement. The award was granted in accordance with Nasdaq Listing Rule 5635(c)(4).
INOVIO (NASDAQ:INO) will participate in two investor conferences in New York in December 2025. Management will appear at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2 for an 8:30–8:55 AM ET fireside chat (live webcast and 90‑day replay available) and at the Oppenheimer Movers in Rare Disease Summit on Thursday, December 11 for a 12:05–12:25 PM ET panel featuring elevator pitches of near‑term catalysts. Members of INOVIO management will also hold one‑on‑one investor meetings during both events.
Webcast link for the Piper Sandler presentation: https://bit.ly/44af19l.
INOVIO (Nasdaq: INO) priced an underwritten public offering of 13,158,000 shares of common stock at $1.90 per share, with expected gross proceeds of approximately $25 million.
The company is selling all offered shares and granted the underwriters a 30-day option to purchase up to 1,973,700 additional shares at the public offering price less discounts and commissions. The offering is expected to close on or about November 12, 2025, subject to customary conditions, with Piper Sandler & Co. acting as sole manager.
A shelf registration was filed on November 9, 2023 and declared effective by the SEC on January 31, 2024. Final prospectus supplement will be available through the underwriter and the SEC EDGAR site.
INOVIO (Nasdaq: INO) announced on November 10, 2025 that it intends to offer and sell shares of its common stock in an underwritten public offering, with all shares to be sold by the company.
INOVIO said it will grant the underwriter a 30-day option to buy up to 15% additional shares on the same terms. The offering is subject to market conditions and there is no assurance of timing, size, or terms. Piper Sandler is acting as sole book-running manager. The shares are covered by a shelf registration filed with the SEC on November 9, 2023 and declared effective on January 31, 2024. The offering will be made only by prospectus and prospectus supplement filed with the SEC.